| Effect of interleukin-6 receptor blockade on the balance between regulatory T cells and T helper type 17 cells in rheumatoid arthritis patients. | |
| | |
MedLine Citation:
|
PMID: 23379428 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
A new paradigm has emerged relating the pathogenesis of rheumatoid arthritis (RA), focused on the balance between T helper type 17 cells and regulatory T cells (T(regs) ). In humans, both subpopulations depend on transforming growth factor (TGF)-β for their induction, but in the presence of inflammatory cytokines, such as interleukin (IL)-6, the generation of Th17 is favoured. Tocilizumab is a therapeutic antibody targeting the IL-6 receptor (IL-6R), which has demonstrated encouraging results in RA. The aim of this study was to evaluate the effect of tocilizumab on Th1 cells, Th17 cells, IL-17 and interferon (IFN)-γ double secretors Th17/Th1 cells, and T(regs) in RA patients. Eight RA patients received tocilizumab monthly for 24 weeks and blood samples were obtained every 8 weeks to study T cell populations by flow cytometry. The frequency of Th17 cells, Th1 cells and Th17/Th1 cells was evaluated in peripheral blood mononuclear cells (PBMCs) activated in vitro with a polyclonal stimulus. T(regs) were identified by their expression of forkhead box protein 3 (FoxP3) and CD25 by direct staining of PBMCs. Although no changes were detected in the frequency of Th1 or Th17 cells, the percentages of peripheral T(regs) increased after therapy. In addition, the infrequent Th17/Th1 subpopulation showed a significant increment in tocilizumab-treated patients. In conclusion, tocilizumab was able to skew the balance between Th17 cells and T(regs) towards a more protective status, which may contribute to the clinical improvement observed in RA patients. |
| | |
Authors:
|
B Pesce; L Soto; F Sabugo; P Wurmann; M Cuchacovich; M N López; P H Sotelo; M C Molina; J C Aguillón; D Catalán |
Related Documents
:
|
23549468 - Immunohistochemical study of doublecortin and nucleostemin in canine brain. 18499898 - Criticality of the biological and physical stimuli array inducing resident cardiac stem... 23560298 - Cd200 upregulation in vascular endothelium surrounding cutaneous squamous cell carcinoma. 23554818 - Improved method for ex ovo-cultivation of developing chicken embryos for human stem cel... 17467668 - Rankl-stimulated tnfalpha production in osteoclast precursor cells promotes osteoclasto... 1715518 - Requirement for mast cell growth factor for primordial germ cell survival in culture. |
Publication Detail:
|
Type: Journal Article; Research Support, Non-U.S. Gov't |
Journal Detail:
|
Title: Clinical and experimental immunology Volume: 171 ISSN: 1365-2249 ISO Abbreviation: Clin. Exp. Immunol. Publication Date: 2013 Mar |
Date Detail:
|
Created Date: 2013-02-05 Completed Date: 2013-04-02 Revised Date: 2013-04-16 |
Medline Journal Info:
|
Nlm Unique ID: 0057202 Medline TA: Clin Exp Immunol Country: England |
Other Details:
|
Languages: eng Pagination: 237-42 Citation Subset: IM |
Copyright Information:
|
© 2012 British Society for Immunology. |
Affiliation:
|
Programa Disciplinario de Inmunología, Instituto de Ciencias Biomédicas, Universidad de Chile/Millennium Institute on Immunology and Immunotherapy-Chile, Santiago, Chile. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adult Antibodies, Monoclonal, Humanized / pharmacology*, therapeutic use Arthritis, Rheumatoid / drug therapy, immunology* Female Humans Middle Aged Receptors, Interleukin-6 / antagonists & inhibitors* T-Lymphocytes, Regulatory / drug effects*, immunology* Th1 Cells / immunology Th17 Cells / drug effects*, immunology* |
| Chemical | |
Reg. No./Substance:
|
0/Antibodies, Monoclonal, Humanized; 0/Receptors, Interleukin-6; 0/tocilizumab |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Associations among depression, anxiety and somatic symptoms in peri- and postmenopausal women.
Next Document: Cellular immune responses in multiple sclerosis patients treated with interferon-beta.